Menstrual cycle variation in mammographic breast density: so who cares?
暂无分享,去创建一个
[1] Albert,et al. THE CHILDREN'S HOSPITAL OF PHILADELPHIA , 1955 .
[2] Gunnar Eklund,et al. Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985 .
[3] J. A. Thomas,et al. Effects of testosterone and prolactin or growth hormone on the accessory sex organs of castrated mice. , 1975, The Journal of endocrinology.
[4] T. Stamey,et al. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.
[5] M. Papa,et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.
[6] A. Schally,et al. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. , 1997, British Journal of Cancer.
[7] David J Hunter,et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.
[8] J. Veldhuis,et al. Demonstration of a lack of racial difference in secretion of growth hormone despite a racial difference in bone mineral density in premenopausal women--a Clinical Research Center study. , 1996, The Journal of clinical endocrinology and metabolism.
[9] Meir J. Stampfer,et al. Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .
[10] S. Rubin,et al. Efficacy of screening mammography. A meta-analysis. , 1995, JAMA.
[11] R. Baxter,et al. Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia , 1997, Clinical endocrinology.
[12] L. Giudice,et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.
[13] C. Mantzoros,et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. , 1997, British Journal of Cancer.
[14] P. Cohen,et al. Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.
[15] P. Stricker,et al. Growth factor involvement in progression of prostate cancer. , 1998, Clinical chemistry.
[16] R Tibshirani,et al. Impact of menstrual phase on false‐negative mammograms in the canadian national breast screening study , 1997, Cancer.
[17] A. Miller,et al. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[18] D. Peehl,et al. The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[19] H. Huynh,et al. Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. , 1998, Endocrinology.
[20] R. Rosenfeld,et al. Assays for insulin-like growth factors and their binding proteins: practicalities and pitfalls. , 1996, The Journal of pediatrics.
[21] J. Elmore,et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.
[22] E White,et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. , 1998, Journal of the National Cancer Institute.
[23] P. Carroll,et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review , 1998 .
[24] I. Powell,et al. Prostate cancer and African-American men. , 1997, Oncology.
[25] P. Marzullo,et al. Prostatic hyperplasia: an unknown feature of acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.
[26] C. Mantzoros,et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.
[27] L. Plöen,et al. Effects of very high doses of human growth hormone (hGH) on the male reproductive system in the dog , 2009, Andrologia.
[28] D C Slawson,et al. Efficacy of screening mammography. , 1995, The Journal of family practice.
[29] J. Yesavage,et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. , 1998, The Journal of clinical endocrinology and metabolism.
[30] S. Humphries,et al. Apal polymorphism in insulin-like growth factor II (IGF2) gene and weight in middle-aged males , 1997, International Journal of Obesity.
[31] S. Mohan,et al. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.
[32] L. Tabár,et al. REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985, The Lancet.
[33] V. Ernster. Mammography screening for women aged 40 through 49--a guidelines saga and a clarion call for informed decision making. , 1997, American journal of public health.
[34] L Nyström,et al. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization. , 1997, Journal of the National Cancer Institute. Monographs.